International ClinicsMedical News
International Clinics Newsroom · · 1 min read
Daily

FDA approves atezolizumab with chemotherapy after surgery for stage III dMMR colon cancer

  • On 8 October 2026 the FDA approved Tecentriq (atezolizumab) with chemotherapy as adjuvant treatment for stage III colon cancer.
  • The atezolizumab approval covers mismatch repair deficient (dMMR) tumours in adults and children aged 2 and older.
  • In the ATOMIC trial of 712 patients, atezolizumab cut the risk of recurrence or death by about 50%.
  • A subcutaneous version of atezolizumab (Tecentriq Hybreza) was approved for the same use from age 12.
Sign at the US Food and Drug Administration headquarters
Sign at the US Food and Drug Administration headquarters Photo: AJMC
Published:

The US Food and Drug Administration approved Genentech's Tecentriq (atezolizumab) on 8 October 2026, combined with a fluoropyrimidine and oxaliplatin, as adjuvant treatment after surgery for adults and children aged 2 and older with stage III mismatch repair deficient (dMMR) colon cancer. A subcutaneous form (Tecentriq Hybreza) was approved for the same use in patients aged 12 and older weighing at least 40 kg.

The trial

Approval rests on the randomized ATOMIC trial of 711 adults and one child after complete removal of the tumour. Patients received either atezolizumab plus mFOLFOX6 for 12 cycles followed by 6 months of atezolizumab alone, or mFOLFOX6 alone.

Also read: FDA grants accelerated approval to dostarlimab for dMMR/MSI-H locally advanced rectal cancer

Results

Atezolizumab halved the risk of recurrence or death (hazard ratio 0.50). In the published trial results, 3-year disease-free survival was 86.3% with atezolizumab versus 76.2% with chemotherapy alone. Overall survival, however, has not differed significantly between the groups so far.

Warnings

The label includes warnings for immune-mediated reactions, infusion reactions and harm to an unborn baby.

Sources: US Food and Drug Administration (FDA), AJMC

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What did the FDA approve for atezolizumab?

On 8 October 2026 the FDA approved atezolizumab (Tecentriq) with a fluoropyrimidine and oxaliplatin as adjuvant treatment after surgery for stage III dMMR colon cancer.

Who can receive atezolizumab for colon cancer?

Intravenous atezolizumab is approved for adults and children aged 2 and older; the subcutaneous form is for patients aged 12 and older weighing at least 40 kg.

How much did atezolizumab lower colon cancer recurrence?

In ATOMIC, atezolizumab plus chemotherapy cut the risk of recurrence or death by about 50% compared with chemotherapy alone.

Did atezolizumab improve overall survival?

Overall survival has not differed significantly between the ATOMIC trial groups so far, although recurrence was lower with atezolizumab.

What does dMMR colon cancer mean?

dMMR colon cancer is a tumour with a defect in the system that repairs DNA copying errors, a type that usually responds to immunotherapy such as atezolizumab.

How would you rate this story?
5,045
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.